Guilin Sanjin Pharmaceutical Co., Ltd.
桂林三金
002275
Shenzhen Stock Exchange
Company Profile
A strong professional and market advantage in throat and oral medicine, and urinary system medicine of the company has come into being. Now it has 47 exclusive characteristic varieties, including Guilin Watermelon Frost, Watermelon Frost Lozenges, Sanjin Tablet, Naomaitai Capsule, etc, which are researched and developed by itself. Successively, 21 varieties of it has obtained 73invention patents for national TCM protection, in which, four patents have won China Patents Excellency Awards, one patent has won the title of National Confidentiality Patent, one patent is a USA patent. Two of its innovation fruits have won National Science and Technology Progress Award, 12 have won Provincial Science and Technology Progress Award. The brand trademark of "Sanjin" has been identified as "China Well-known Trademark" by the State Administration for Industry and Commerce , and "Time-honored Brand of Guangxi” by Guangxi Department of Commerce, and has been listed as "China 500 Most Valuable Brands" by the "World Brand Lab"for many consecutive years .The company has a state-level technology center and a postdoctoral research station, as well as Guangxi TCM Industrialization Engineering Institute, Guangxi Engineering Technologic Research Center for Modern Proprietary Chinese Medicine, Guangxi’s one hundred billion yuan industry - Guangxi New Chinese Medicine Research and Development Center, Guangxi main carrier unit for medical talent highland, and the company is also a unit with positions for "Guangxi Scholars" in Guangxi. In 2010, Sanjin was officially approved by the Ministry of Science and Technology as a national innovation-oriented pilot enterprise. In 2014, it was awarded the national technology innovation demonstration enterprise by the Ministry of Industry and Information Technology.
Full description
The company's main business involves the research, development, manufacturing, and sales of traditional Chinese patent medicines and simple preparations, while also covering multiple sub-sectors such as chemical drugs, biological drugs, daily health products, and comprehensive health products. The company adheres to the corporate vision of "Becoming China's leading pharmaceutical manufacturing group" and continuously promotes the "one body, two wings" development strategy, with traditional Chinese medicine as the core and foundation of the pharmaceutical industry as the main body, biopharmaceuticals as the focus of the biotechnology industry and comprehensive health industry as the two wings, and related industries as supplements. It also continuously consolidates or strengthens its leadership or leading position in areas such as oral and throat medications and urinary system medications.